
Virtual Tumor Board: Stage III ALK+ NSCLC
Virtual Tumor Board: Stage III ALK+ NSCLC by IASLC
5 Mar 202548min

Live from TTLC25: Targeted Therapy in Early Stage NSCLC Debate
Live from TTLC25: Targeted Therapy in Early Stage NSCLC Debate by IASLC
28 Feb 202525min

The Benefits of Patient Advocacy Groups
In this episode of Lung Cancer Considered, host Dr. Narjust Florez engages in a discussion with patient advocate Summer Farmen. Listen to the episode to learn about Summer’s journey through diagnosis ...
24 Feb 202530min

Live from TTLC25: Targeted Therapy in SCLC
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on how small cell lung cancer continues to evolve with new treatment options and recent FDA approval. Listen to th...
20 Feb 202529min

Live from TTLC 2025: Mesothelioma and NUT Carcinoma
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of two of the most challenging thoracic malignancies – NUT carcinoma and mesothelioma. Listen to the episode to le...
20 Feb 202544min

LCC in Arabic: Chemo Immunotherapy in Metastatic NSCLC
Descriptions: As part of the IASLC's ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Bashir Abu Aqeel and Dr. Fawzi Abu Rous. The group d...
14 Feb 202515min

Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case involving drug resistance in EGFR mutant NSCLC. This discussion takes the listener through the tr...
11 Feb 202545min

LAURA Study (Part 2) - Radiation Oncology Perspective
This episode of Lung Cancer Considered covers the recent FDA approval of Osimertinib after chemo-radiation in EGFR positive NSCLC based on the LAURA trial which was presented at the 2024 ASCO Annual M...
4 Feb 202547min


















